Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Marimed (MRMD) Interest Expenses (2016 - 2025)

Marimed has reported Interest Expenses over the past 12 years, most recently at $2.2 million for Q4 2025.

  • Quarterly Interest Expenses rose 14.16% to $2.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.5 million through Dec 2025, up 8.04% year-over-year, with the annual reading at $7.5 million for FY2025, 8.04% up from the prior year.
  • Interest Expenses was $2.2 million for Q4 2025 at Marimed, up from $1.8 million in the prior quarter.
  • Over five years, Interest Expenses peaked at $2.6 million in Q2 2023 and troughed at $200000.0 in Q1 2021.
  • The 5-year median for Interest Expenses is $1.7 million (2024), against an average of $1.3 million.
  • Year-over-year, Interest Expenses crashed 92.57% in 2021 and then skyrocketed 700.32% in 2023.
  • A 5-year view of Interest Expenses shows it stood at $279000.0 in 2021, then soared by 51.25% to $422000.0 in 2022, then skyrocketed by 269.19% to $1.6 million in 2023, then rose by 21.05% to $1.9 million in 2024, then grew by 14.16% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Interest Expenses are $2.2 million (Q4 2025), $1.8 million (Q3 2025), and $1.8 million (Q2 2025).